Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis（UPRISE）

Exclusion Criteria

• •Presence of contraindications, allergy, or intolerance to upadacitinib or infliximab.
• •Patients requiring immediate colectomy; diagnosis of Crohn's disease; confirmed intestinal infection; hemodynamic instability; clinically significant cytomegalovirus infection; current malignancy.
• •Presence of severe underlying systemic diseases involving the heart, lungs, liver, kidneys, hematologic system, or other organ systems.
• •Pregnant or breastfeeding women.
• •Unwilling to participate in the clinical study.